As variant viruses are spreading in many countries, the demand for PCR testing has increased greatly, and the August revenue of testing reagent factories, including GeneReach and TANBead, still had a bright performance, which also motivated the stock prices of related anti-epidemic concepts to attack strongly against the trend.
GeneReach Biotechnology reported a revenue of NT$106 million in August, an annual growth of 45.65%, and a cumulative revenue of NT$710 million from January to August, an annual growth of 38.98%. GeneReach said that the COVID-19 outbreak in many countries due to variant viruses, the situation continues to change repeatedly, the demand for PCR testing continues to rise, the company's revenue has been injected accordingly. GeneReach said, in order to prevent the variant virus epidemic, Taiwan daily COVID-19 PCR testing demand has increased greatly, the current 240 qualified contracted detection units in Taiwan, the use of GeneReach products unit has reached 90; Internationally, in addition to Indonesia and the Middle East, the United States, Africa and other continuous shipments, Japan and Brazil are also actively carrying out the relevant certifications of the local imports.
Looking forward to the second half of the year, the international African Swine Fever (ASF) epidemic is on the rising trend. GeneReach is in close contact with the livestock agents in Central and South America to share the application of the relevant products in ASF prevention and the experience in Asia, and is expected to hold a seminar on ASF in September, which is expected to have a positive impact on the market of GeneReach's products in the field of animal health management.
The domestic manufacturer of nucleic acid purification reagents and nucleic acid extraction instruments, TANBead, pushed by steady growth in overseas shipments, reported a revenue of NT$140 million in August, a monthly increase of 11%, up for two successive months, and a cumulative total of NT$1.38 billion from January to August, an increase of 124% compared to the same period of last year. TANBead's stock price rose to NT$198.5 today, up more than 4%.
TANBead stated that the company has been actively cultivating the global market, with stable development in Europe, the U.S. and Korea. The recent severe epidemic in Southeast Asia has led to a significant increase in shipments from Vietnam, Thailand, Indonesia and other Southeast Asian countries, as well as winning many large-scale hospital bids, which has contributed to the growth of revenues.
